Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, Fred Saad
{"title":"前列腺癌生物标志物的现状与未来:蛋白质组学、基因组学和免疫学的发展。","authors":"Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, Fred Saad","doi":"10.4137/BIC.S31802","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PC) is the second most common form of cancer in men worldwide. Biomarkers have emerged as essential tools for treatment and assessment since the variability of disease behavior, the cost and diversity of treatments, and the related impairment of quality of life have given rise to a need for a personalized approach. High-throughput technology platforms in proteomics and genomics have accelerated the development of biomarkers. Furthermore, recent successes of several new agents in PC, including immunotherapy, have stimulated the search for predictors of response and resistance and have improved the understanding of the biological mechanisms at work. This review provides an overview of currently established biomarkers in PC, as well as a selection of the most promising biomarkers within these particular fields of development. </p>","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859450/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.\",\"authors\":\"Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, Fred Saad\",\"doi\":\"10.4137/BIC.S31802\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prostate cancer (PC) is the second most common form of cancer in men worldwide. Biomarkers have emerged as essential tools for treatment and assessment since the variability of disease behavior, the cost and diversity of treatments, and the related impairment of quality of life have given rise to a need for a personalized approach. High-throughput technology platforms in proteomics and genomics have accelerated the development of biomarkers. Furthermore, recent successes of several new agents in PC, including immunotherapy, have stimulated the search for predictors of response and resistance and have improved the understanding of the biological mechanisms at work. This review provides an overview of currently established biomarkers in PC, as well as a selection of the most promising biomarkers within these particular fields of development. </p>\",\"PeriodicalId\":72377,\"journal\":{\"name\":\"Biomarkers in cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859450/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/BIC.S31802\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/BIC.S31802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
前列腺癌(PC)是全球男性第二大常见癌症。生物标志物已成为治疗和评估的重要工具,因为疾病行为的多变性、治疗的成本和多样性,以及相关的生活质量损害,使得人们需要一种个性化的方法。蛋白质组学和基因组学的高通量技术平台加速了生物标志物的开发。此外,最近包括免疫疗法在内的几种新药在 PC 领域取得的成功也促进了对反应和耐药性预测指标的研究,并加深了人们对其生物作用机制的了解。本综述概述了 PC 领域目前已确立的生物标志物,并选择了这些特定发展领域中最有前景的生物标志物。
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.
Prostate cancer (PC) is the second most common form of cancer in men worldwide. Biomarkers have emerged as essential tools for treatment and assessment since the variability of disease behavior, the cost and diversity of treatments, and the related impairment of quality of life have given rise to a need for a personalized approach. High-throughput technology platforms in proteomics and genomics have accelerated the development of biomarkers. Furthermore, recent successes of several new agents in PC, including immunotherapy, have stimulated the search for predictors of response and resistance and have improved the understanding of the biological mechanisms at work. This review provides an overview of currently established biomarkers in PC, as well as a selection of the most promising biomarkers within these particular fields of development.